Evidence map›Paper›PMID 33647393›Full record

Trial reportAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2021

Association of Urine Biomarkers of Kidney Tubule Injury and Dysfunction With Frailty Index and Cognitive Function in Persons With CKD in SPRINT.

Lindsay M Miller, Dena Rifkin, Alexandra K Lee, Manjula Kurella Tamura, Nicholas M Pajewski, Daniel E Weiner, Tala Al-Rousan, Michael Shlipak, Joachim H Ix

Open access · greenAbstract readObservational StudyRandomized Controlled Trial
In one paragraph

Trial report in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Uremic Toxins, CKD, and Cognitive Dysfunction.Journal of the American Society of Nephrology : JASN · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Lindsay M MillerDivision of Nephrology-Hypertension, University of California-San Diego, San Diego, California. Electronic address: Lmmiller@health.ucsd.edu.
Dena RifkinDivision of Nephrology-Hypertension, University of California-San Diego, San Diego, California; Veterans Affairs San Diego Healthcare System, San Diego, California.
Alexandra K LeeSchool of Medicine, University of California-San Francisco, San Francisco, California.
Manjula Kurella TamuraDivision of Nephrology, Department of Medicine, Stanford University, and Palo Alto Veterans Affairs Health Care System, Palo Alto, California.
Nicholas M PajewskiDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Daniel E WeinerDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts.
Tala Al-RousanHerbert Wertheim School of Public Health, University of California San Diego, La Jolla, California.
Michael ShlipakSchool of Medicine, University of California-San Francisco, San Francisco, California.
Joachim H IxDivision of Nephrology-Hypertension, University of California-San Diego, San Diego, California; Veterans Affairs San Diego Healthcare System, San Diego, California.
University of California, San Diego · USUniversity of California, San Francisco · USTufts Medical Center · USVA Palo Alto Health Care System · USVA San Diego Healthcare System · USWake Forest University · US

Funding

INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Wake Forest Claude D. Pepper OAIC - RenewalP30AG021332 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LEON LENCHIK · 2002 to 2026
$36.4M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Tufts Clinical and Translational Research InstituteUL1TR001064 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2013 to 2017
$26.4M
University of Iowa Clinical and Translational Science Program (TL1)UL1RR025755 · NCRR · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2008 to 2011
$26.3M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025771 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CENTER, DAVID M. · 2008 to 2011
$17.6M
NCATS NIH HHS UL1 TR000002NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR000005NCATS NIH HHS UL1 TR000050NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR000073NCATS NIH HHS UL1 TR000075NCATS NIH HHS UL1 TR000093NCATS NIH HHS UL1 TR000105NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR001064NCATS NIH HHS UL1 TR002548NCATS NIH HHS UL1 TR003142NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1 RR025752NCRR NIH HHS UL1 RR025755NCRR NIH HHS UL1 RR025771NHLBI NIH HHS HHSN268200900040CNHLBI NIH HHS HHSN268200900046CNHLBI NIH HHS HHSN268200900047CNHLBI NIH HHS HHSN268200900048CNHLBI NIH HHS HHSN268200900049CNHLBI NIH HHS K23 HL148530NIA NIH HHS P30 AG021332NIA NIH HHS R01 AG055606NIA NIH HHS T32 AG000212NIDDK NIH HHS K24 DK110427NIDDK NIH HHS R01 DK092241NIDDK NIH HHS R01 DK098234NIDDK NIH HHS T32 DK104717NIGMS NIH HHS P30 GM103337
6 · The paper itself

Abstract

RATIONALE &

objectiveThe associations of the glomerular markers of kidney disease, estimated glomerular filtration rate (eGFR) and albuminuria, with frailty and cognition are well established. However, the relationship of kidney tubule injury and dysfunction with frailty and cognition is unknown. STUDY

designObservational cross-sectional study. SETTING &

participants2,253 participants with eGFR<60mL/min/1.73m EXPOSURE: Eight urine biomarkers: interleukin 18 (IL-18), kidney injury molecule 1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), chitinase-3-like protein 1 (YKL-40), monocyte chemoattractant protein 1 (MCP-1), α OUTCOME: Frailty was measured using a previously validated frailty index (FI), categorized as fit (FI≤0.10), less fit (0.10<FI≤0.21), and frail (FI>0.21). Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). ANALYTICAL APPROACH: Associations between kidney tubule biomarkers with categorical FI were evaluated using multinomial logistic regression with the fit group as the reference. Cognitive function was evaluated using linear regression. Models were adjusted for demographic, behavioral, and clinical variables including eGFR and urine albumin.

resultsThree of the 8 urine biomarkers of tubule injury and dysfunction were independently associated with FI. Each 2-fold higher level of urine KIM-1, a marker of tubule injury, was associated with a 1.22 (95% CI, 1.01-1.49) greater odds of being in the frail group. MCP-1, a marker of tubulointerstitial fibrosis, was associated with a 1.30 (95% CI, 1.04-1.64) greater odds of being in the frail group, and A1M, a marker of tubule reabsorptive capacity, was associated with a 1.48 (95% CI, 1.11-1.96) greater odds of being in the frail group. These associations were independent of confounders including eGFR and urine albumin, and were stronger than those of urine albumin with FI (1.15 [95% CI, 0.99-1.34]). Higher urine B2M, another marker of tubule reabsorptive capacity, was associated with worse cognitive scores at baseline (β: -0.09 [95% CI, -0.17 to-0.01]). Urine albumin was not associated with cognitive function. LIMITATIONS: Cross-sectional design, and FI may not be generalizable in other populations.

conclusionsUrine biomarkers of tubule injury, fibrosis, and proximal tubule reabsorptive capacity are variably associated with FI and worse cognition, independent of glomerular markers of kidney health. Future studies are needed to validate these results among other patient populations.

Indexed as

AgedAged, 80 and overBiomarkersBlood PressureChemokine CCL2CognitionCross-Sectional StudiesFemaleFrailtyGlomerular Filtration RateHepatitis A Virus Cellular Receptor 1HumansKidney TubulesMaleMiddle AgedRenal Insufficiency, ChronicBiomarkersCCL2 protein, humanChemokine CCL2HAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1Cognitioncognitive functioncognitive impairmentfitnessfrailtyfunctional statuskidney functionkidney injurymemoryrenal fibrosistubular dysfunctiontubule injurytubule reabsorptive capacityurine biomarkersvascular aging

Identifiers

PMID33647393
PMCPMC8390569
OpenAlexW3135446504

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.